Shares of biotech giant Acadia Pharmaceuticals were deep in the red in Wednesday trading after a company spokesperson and the FDA confirmed that the FDA has launched a safety review on its Parkinson’s Disease drug Nuplazid. Shares fell over 20% after Wall Street learned the news. It was not long ago that CNN had a … Continue reading “Acadia Shares Fall After FDA Launches Safety Review on its Parkinson’s Disease Medication”
